Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients A Cost-Effectiveness Analysis

被引:19
|
作者
Eckman, Mark H. [1 ]
Woodle, E. Steve [2 ,3 ]
Thakar, Charuhas V. [2 ,4 ]
Paterno, Flavio [2 ,3 ]
Sherman, Kenneth E. [2 ,5 ]
机构
[1] Univ Cincinnati, Med Ctr, Dept Internal Med, 231 Albert Sabin Way,POB 670535, Cincinnati, OH 45267 USA
[2] Univ Cincinnati, Cincinnati, OH USA
[3] Dept Surg, 231 Albert Sabin Way,POB 0558, Cincinnati, OH 45267 USA
[4] Dept Internal Med, 231 Albert Sabin Way,POB 0585, Cincinnati, OH 45267 USA
[5] Dept Internal Med, 231 Albert Sabin Way,POB 0595, Cincinnati, OH 45267 USA
关键词
GENOTYPE; 1; INFECTION; TREATMENT-EXPERIENCED PATIENTS; HEALTH-STATE UTILITIES; QUALITY-OF-LIFE; LIVER-TRANSPLANTATION; UNITED-STATES; TREATMENT-NAIVE; POSITIVE KIDNEYS; DISEASE; DIALYSIS;
D O I
10.7326/M17-3088
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Direct-acting antiviral agents are now available to treat chronic hepatitis C virus (HCV) infection in patients with end-stage renal disease (ESRD). Objective: To examine whether it is more cost-effective to transplant HCV-infected or HCV-uninfected kidneys into HCVinfected patients. Design: Markov state-transition decision model. Data Sources: MEDLINE searches and bibliographies from relevant English-language articles. Target Population: HCV-infected patients with ESRD receiving hemodialysis in the United States. Time Horizon: Lifetime. Perspective: Health care system. Intervention: Transplant of an HCV-infected kidney followed by HCV treatment versus transplant of an HCV-uninfected kidney preceded by HCV treatment. Outcome Measures: Effectiveness, measured in qualityadjusted life-years (QALYs), and costs, measured in 2017 U. S. dollars. Results of Base-Case Analysis: Transplant of an HCV-infected kidney followed by HCV treatment was more effective and less costly than transplant of an HCV-uninfected kidney preceded by HCV treatment, largely because of longer wait times for uninfected kidneys. A typical 57.8-year-old patient receiving hemodialysis would gain an average of 0.50 QALY at a lifetime cost savings of $ 41 591 . Results of Sensitivity Analysis: Transplant of an HCV-infected kidney followed by HCV treatment continued to be preferred in sensitivity analyses of many model parameters. Transplant of an HCV-uninfected kidney preceded by HCV treatment was not preferred unless the additional wait time for an uninfected kidney was less than 161 days. Limitation: The study did not consider the benefit of decreased HCV transmission from treating HCV-infected patients. Conclusion: Transplanting HCV-infected kidneys into HCVinfected patients increased quality-adjusted life expectancy and reduced costs compared with transplanting HCV-uninfected kidneys into HCV-infected patients.
引用
收藏
页码:214 / +
页数:11
相关论文
共 50 条
  • [41] Analysis of interferon signal expression in hepatitis C virus-infected patients' lymphocytes
    Tanaka, T
    Asao, K
    Inoue, K
    Kohara-Tsukiyama, K
    Kohara, M
    GASTROENTEROLOGY, 2001, 120 (05) : A570 - A570
  • [42] Temporal changes in the utilization of kidneys from hepatitis C virus-infected donors in the United States
    Buchanan-Peart, Keri-Ann
    Pagan, Javier
    Martin, Eric
    Turkeltaub, Joshua
    Reese, Peter
    Goldberg, David S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : 831 - 838
  • [43] Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: A prospective, randomized trial
    Martin, P
    Busuttil, RW
    Goldstein, RM
    Crippin, JS
    Klintmalm, GB
    Fitzsimmons, WE
    Uleman, C
    LIVER TRANSPLANTATION, 2004, 10 (10) : 1258 - 1262
  • [44] Transplanting Hepatitis C Infected Organs Into Uninfected Recipients: A Pharmacy Perspective
    Holt, M. L.
    James, A.
    Gutierrez, K.
    Sparkman, T.
    Banbury, J.
    Jones, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 484 - 485
  • [45] Kidney Transplantation From Hepatitis C Virus-Infected Donors to Uninfected Recipients: A Systematic Review for the KDIGO 2022 Hepatitis C Clinical Practice Guideline Update
    Gordon, Craig E.
    Adam, Gaelen P.
    Jadoul, Michel
    Martin, Paul
    Balk, Ethan M.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2023, 82 (04) : 410 - 418
  • [46] Seroprevalance of Hepatitis B Virus and Hepatitis C Virus Infections in Human Immunodefi ciency Virus-Infected Patients
    Ural, Serap
    Kaptan, Figen
    Turker, Nesrin
    Ormen, Bahar
    El, Sibel
    Coskun, Nejat Ali
    Demir, Cemanur
    Turker, Metin
    KLIMIK JOURNAL, 2010, 23 (03) : 100 - 104
  • [47] Evaluation of hepatitis B and hepatitis C virus-infected renal allograft recipients with liver biopsy and noninvasive parameters
    Fehr, T
    Riehle, HM
    Nigg, L
    Grüter, E
    Ammann, P
    Renner, EL
    Ambühl, PM
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 42 (01) : 193 - 201
  • [48] Kidney Transplantation From a Hepatitis C Virus-Infected Donor Into an Uninfected Recipient: Ready for Prime Time?
    Pagan, Javier
    Ladino, Marco
    Roth, David
    KIDNEY INTERNATIONAL REPORTS, 2020, 5 (04): : 386 - 388
  • [49] Hepatitis C virus-infected patients report communication problems with physicians
    Zickmund, S
    Hillis, SL
    Barnett, MJ
    Ippolito, L
    LaBrecque, DR
    HEPATOLOGY, 2004, 39 (04) : 999 - 1007
  • [50] Immunosuppression in Hepatitis C Virus-Infected Patients after Kidney Transplantation
    Manuel, Oriol
    Baid-Agrawal, Seema
    Moradpour, Darius
    Pascual, Manuel
    HEPATITIS C IN RENAL DISEASE, HEMODIALYSIS AND TRANSPLANTATION, 2012, 176 : 97 - 107